EVOX THERAPEUTICS LTD.

In News

Evox Therapeutics Partners with Rett Syndrome Research Trust to Evaluate ExoEdit - Business Wire

Business Wire - Feb 26, 2026

Evox Therapeutics Appoints Douglas Treco, Ph.D., to Board of Directors - Business Wire

Business Wire - Nov 11, 2025

Evox Therapeutics Taps Dr. Per Lundin as CEO - Contract Pharma

Contract Pharma - Apr 29, 2024

Top 4 Most Richly Funded Exosome Startups - BioInformant

BioInformant - Sep 11, 2024

Evox Therapeutics signs US$1.2bn deal with Eli Lilly - European Biotechnology Magazine

European Biotechnology Magazine - Jun 10, 2020

Engineering of extracellular vesicles for efficient intracellular delivery of multimodal therapeutics including genome editors - Nature

Nature - Apr 29, 2025

Novel Endogenous Engineering Platform for Robust Loading and Delivery of Functional mRNA by Extracellular Vesicles - Wiley & Sons

Wiley & Sons - Sep 09, 2024

Exosome Therapeutics Market Size to Hit USD 4,564.32 Thousand by 2035 - Precedence Research

Precedence Research - Oct 06, 2025

The Emerging Role of Exosome Therapeutics in 2026 - BioInformant

BioInformant - Jun 21, 2026

Tony de Fougerolles joins Evox Therapeutics as CEO - PMLiVE

PMLiVE - Nov 22, 2017

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment